- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
XVIVO Perfusion’s warrant program 2020/2022
On 31 March 2020, the annual general meeting of XVIVO Perfusion AB (publ) (“XVIVO”) resolved to issue up to 408,000 warrants of series 2020/2022 to employees of XVIVO and XVIVO’s Swedish subsidiaries. The application period to subscribe for warrants ended on September 23, 2020 and a total of 374,000 warrants were subscribed for.
Employees who have subscribed for warrants have paid an option premium corresponding to the market value calculated in accordance with the Black & Scholes valuation model. Each warrant entitles to subscription for one new share in XVIVO during the period 2 May–31 May 2022 for a subscription price of SEK 205.88, which corresponds to 150 percent of the volume weighted average price for XVIVO’s shares listed on Nasdaq Stockholm for each trading day during the period 4 May–15 May 2020. The application period to subscribe for warrants ended on 23 September 2020 and a total of 374,000 warrants were subscribed for. The last subscriptions were made on June 2, 2020.
If all warrants are exercised, XVIVO’s share capital will increase by approximately SEK 9,559 corresponding to a dilution of approximately 1.4 percent of the total number of shares and votes in XVIVO.
Gothenburg, 24 September 2020
XVIVO Perfusion AB (publ)
For further information please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com
About Us
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
